Literature DB >> 10223563

The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.

J Lüttges1, B Schlehe, M A Menke, I Vogel, D Henne-Bruns, G Klöppel.   

Abstract

BACKGROUND: Hyperplastic ductal lesions of the pancreas are believed to represent precursors of ductal adenocarcinoma. The most frequent mutation in manifest ductal carcinoma of the pancreas is the K-ras mutation at codon 12. The frequency and significance of this mutation in precursor lesions are a matter of controversy.
METHODS: The study included 35 resection specimens of ductal adenocarcinoma of the head of the pancreas and 3 noncancerous, noninflammatory pancreases. Ductal lesions were classified according to established criteria. Single cells from these lesions were microdissected and analyzed by the denaturing gradient gel electrophoresis polymerase chain reaction method.
RESULTS: All primary adenocarcinomas showed a K-ras mutation at codon 12 (25 cases with GAT, 7 cases with GTT, and 3 cases with CGT). One hundred and six of 364 ductal lesions were positive for the mutation. The highest relative percentage (53%) occurred in adenomatoid hyperplasia, followed by 36% in papillary hyperplasia, 26% in mucinous hypertrophy, and 14% in squamous metaplasia. With only two exceptions the mutation pattern of the ductal lesions and that of the corresponding primary tumor were identical. Twenty-one samples from normal ducts (17%) also harbored the K-ras mutation, as did 3 lesions from noncancerous specimens.
CONCLUSIONS: K-ras mutations are common events in normal, hyperplastic, metaplastic, and neoplastic pancreatic ductal cells. Because K-ras mutations frequently, although not exclusively, are related to mucinous differentiation of pancreatic cells, this mutation may not cause but only promote mucinous differentiation. The prevalence of a certain mutation pattern in nonneoplastic and neoplastic ductal cells in an individual pancreas suggests the dominance of one carcinogenic factor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223563

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis.

Authors:  N Howes; J P Neoptolemos
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 3.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

4.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 5.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

6.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

7.  High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).

Authors:  Nir Lubezky; Menahem Ben-Haim; Sylvia Marmor; Eli Brazowsky; Gideon Rechavi; Joseph M Klausner; Yoram Cohen
Journal:  J Gastrointest Surg       Date:  2011-01-12       Impact factor: 3.452

Review 8.  Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State.

Authors:  Masoud H Manjili
Journal:  Cancer Res       Date:  2017-05-15       Impact factor: 12.701

9.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

10.  Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer.

Authors:  Guo-Xiong Zhou; Jie-Fei Huang; Zhao-Shen Li; Guo-Ming Xu; Feng Liu; Hong Zhang
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.